Cosentyx

Moderate to severe plaque psoriasis in patients ≥6 yr who are candidates for systemic therapy or phototherapy. Monotherapy or in combination w/ MTX for active psoriatic arthritis in adult patients when response to previous DMARD therapy has been inadequate. Axial spondyloarthritis (axSpA) w/ or w/o radiographic damage. Ankylosing spondylitis (AS)/axSpA w/ radiographic damage in adult patients who have responded inadequately to conventional therapy. Active non-radiographic axial spondyloarthritis (nr-axSpA) w/ objective signs of inflammation as indicated by elevated C-reactive protein &/or MRI evidence in adult patients w/ inadequate response to or are intolerant of NSAIDs. Active enthesitis-related arthritis (ERA) or juvenile psoriatic arthritis (JPsA) in patients ≥6 yr whose disease has responded inadequately to or who cannot tolerate conventional therapy. Moderate to severe hidradenitis suppurativa in adult patients w/ inadequate response to conventional systemic therapy.

SC Plaque psoriasis Adult 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. Maintenance: 300 mg every 2 wk may provide additional benefit for patients weighing ≥90 kg. Each 300 mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. Ped weighing ≥50 kg 150 mg, may be increased to 300 mg, 25 to <50 kg 75 mg, <25 kg 75 mg. Administer w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing (every 4 wk). Each 300 mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. Psoriatic arthritis 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. May increase dose to 300 mg based on clinical response. Patient w/ concomitant moderate to severe plaque psoriasis & those who are anti-TNF-α inadequate responders 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. Each 300 mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. AS 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. May increase dose to 300 mg based on clinical response. Each 300 mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. nr-axSpA 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 by mthly maintenance dosing. ERA & JPsA Patient weighing ≥50 kg 150 mg, <50 kg 75 mg. Administer at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing (every 4 wk). Each 75 mg dose is given as 1 SC inj of 75 mg. Each 150 mg dose is given as 1 SC inj of 150 mg. May be administered w/ or w/o MTX. Hidradenitis suppurativa 300 mg w/ initial dosing at wk 0, 1, 2, 3 & 4, followed by mthly maintenance dosing. May increase dose to 300 mg every 2 wk based on clinical response. Each 300 mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg.

Hypersensitivity.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations

L04AC10 - secukinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

POM